Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 2 Study of Rasagiline for Treatment of Amyotrophic Lateral Sclerosis

NCT01786603 is registered in ClinicalTrials.gov with Richard Barohn, MD as lead sponsor.

NCT NCT01786603
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01786603 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 2 Study of Rasagiline for Treatment of Amyotrophic Lateral Sclerosis
Lead sponsor
Richard Barohn, MD
Phase
Phase 2
Overall status
Completed
Start date
November 21, 2013
Completion date
July 27, 2016
Enrollment
80 (actual)
Sites
10

Conditions

As the registry lists them; a condition with its own page is linked.

amyotrophic lateral sclerosis (als)